146 related articles for article (PubMed ID: 38102390)
1. Mutated ASXL1 upregulates mTOR expression in renal cell carcinoma with fibromyomatous stroma.
Liu Y; Zhou L; Xu H; Gu Y; Dong L; Yang X; Wang C
Virchows Arch; 2023 Dec; ():. PubMed ID: 38102390
[TBL] [Abstract][Full Text] [Related]
2. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
[TBL] [Abstract][Full Text] [Related]
3. Renal Cell Carcinoma With Fibromyomatous Stroma-The Whole Story.
Shah RB
Adv Anat Pathol; 2022 May; 29(3):168-177. PubMed ID: 35249990
[TBL] [Abstract][Full Text] [Related]
4. Positive GPNMB Immunostaining Differentiates Renal Cell Carcinoma With Fibromyomatous Stroma Associated With TSC1/2/MTOR Alterations From Others.
Li H; Argani P; Halper-Stromberg E; Lotan TL; Merino MJ; Reuter VE; Matoso A
Am J Surg Pathol; 2023 Nov; 47(11):1267-1273. PubMed ID: 37661807
[TBL] [Abstract][Full Text] [Related]
5. Biallelic ELOC-Inactivated Renal Cell Carcinoma: Molecular Features Supporting Classification as a Distinct Entity.
Batavia AA; Rutishauser D; Sobottka B; Schraml P; Beerenwinkel N; Moch H
Mod Pathol; 2023 Aug; 36(8):100194. PubMed ID: 37088333
[TBL] [Abstract][Full Text] [Related]
6. New insights in the new WHO classification of adult renal tumors.
Hes O; Michalová K; Pivovarčíková K
Cesk Patol; 2022; 67(4):187-191. PubMed ID: 36513503
[TBL] [Abstract][Full Text] [Related]
7. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
[TBL] [Abstract][Full Text] [Related]
8. Analysis of clinicopathological and molecular features of ELOC(TCEB1)-mutant renal cell carcinoma.
Wang Y; Zhao P; Wang L; Wang J; Ji X; Li Y; Shi H; Li Y; Zhang W; Jiang Y
Pathol Res Pract; 2022 Jul; 235():153960. PubMed ID: 35653922
[TBL] [Abstract][Full Text] [Related]
9. Renal Cell Carcinoma With Fibromyomatous Stroma: A New Case.
Haouane MA; Hajji F; Ghoundale O; Azami MA
Cureus; 2022 Dec; 14(12):e32238. PubMed ID: 36620787
[TBL] [Abstract][Full Text] [Related]
10. TSC/MTOR -associated Eosinophilic Renal Tumors Exhibit a Heterogeneous Clinicopathologic Spectrum : A Targeted Next-generation Sequencing and Gene Expression Profiling Study.
Xia QY; Wang XT; Zhao M; He HY; Fang R; Ye SB; Li R; Wang X; Zhang RS; Lu ZF; Ma HH; Wang ZY; Rao Q
Am J Surg Pathol; 2022 Nov; 46(11):1562-1576. PubMed ID: 35980750
[TBL] [Abstract][Full Text] [Related]
11. Recurrent
Palathingal Bava E; Gupta N; Alruwaii FI; Nelson R; Al-Obaidy KI
Int J Surg Pathol; 2024 Feb; ():10668969241228295. PubMed ID: 38311893
[TBL] [Abstract][Full Text] [Related]
12. Are Renal Cell Carcinoma with Fibromyomatous Stroma (RCC-FMS) and Thyroid-like Follicular Carcinoma of the Kidney (TLFCK) Really Independent Variants?
Stanca S; Boldrini L; Erba PA; Faviana P
Diagnostics (Basel); 2022 Dec; 13(1):. PubMed ID: 36611378
[TBL] [Abstract][Full Text] [Related]
13. Current Knowledge and Prospects for Renal Hemangioblastoma and Renal Cell Carcinoma with Hemangioblastoma-like Features.
Kojima F; Musangile FY; Matsuzaki I; Yorita K; Kuroda N; Nagashima Y; Murata SI
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239138
[TBL] [Abstract][Full Text] [Related]
14. Recent Advances in Renal Tumors with TSC/mTOR Pathway Abnormalities in Patients with Tuberous Sclerosis Complex and in the Sporadic Setting.
Kapur P; Brugarolas J; Trpkov K
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627070
[TBL] [Abstract][Full Text] [Related]
15. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
16. TSC/MTOR-mutated eosinophilic renal tumors are a distinct entity that is CK7+/CK20-/vimentin-: a validation study.
Tjota MY; Wanjari P; Segal J; Antic T
Hum Pathol; 2021 Sep; 115():84-95. PubMed ID: 33352195
[TBL] [Abstract][Full Text] [Related]
17. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
Hartmann A; Agaimy A
Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
[TBL] [Abstract][Full Text] [Related]
18. Novel, emerging and provisional renal entities: The Genitourinary Pathology Society (GUPS) update on renal neoplasia.
Trpkov K; Williamson SR; Gill AJ; Adeniran AJ; Agaimy A; Alaghehbandan R; Amin MB; Argani P; Chen YB; Cheng L; Epstein JI; Cheville JC; Comperat E; da Cunha IW; Gordetsky JB; Gupta S; He H; Hirsch MS; Humphrey PA; Kapur P; Kojima F; Lopez JI; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Menon S; Netto GJ; Przybycin CG; Rao P; Rao Q; Reuter VE; Saleeb RM; Shah RB; Smith SC; Tickoo S; Tretiakova MS; True L; Verkarre V; Wobker SE; Zhou M; Hes O
Mod Pathol; 2021 Jun; 34(6):1167-1184. PubMed ID: 33526874
[TBL] [Abstract][Full Text] [Related]
19.
Zhang KJ; Qu Z; Pszenica E; Hafron JM; Zhang PL; Brown RE
Ann Clin Lab Sci; 2023 Jan; 53(1):3-13. PubMed ID: 36889765
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic solid and cystic renal cell carcinoma and renal cell carcinomas with TFEB alterations: a comparative study.
Lobo J; Rechsteiner M; Helmchen BM; Rupp NJ; Weber A; Moch H
Histopathology; 2022 Jul; 81(1):32-43. PubMed ID: 35403742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
